Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

NCT01187303 is registered in ClinicalTrials.gov with University of Cologne as lead sponsor.

NCT NCT01187303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01187303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
Lead sponsor
University of Cologne
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2011
Completion date
September 30, 2015
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed nlphl